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An increase in transmitter release accompanying long-term sensi-
tization and facilitation occurs at the glutamatergic sensorimotor
synapse of Aplysia. We report that a long-term increase in neuronal
Glu uptake also accompanies long-term sensitization. Synapto-
somes from pleural-pedal ganglia exhibited sodium-dependent,
high-affinity Glu transport. Different treatments that induce long-
term enhancement of the siphon-withdrawal reflex, or long-term
synaptic facilitation increased Glu uptake. Moreover, 5-hydroxy-
tryptamine, a treatment that induces long-term facilitation, also
produced a long-term increase in Glu uptake in cultures of sensory
neurons. The mechanism for the increase in uptake is an increase
in the Vmax of transport. The long-term increase in Glu uptake
appeared to be dependent on mRNA and protein synthesis, and
transport through the Golgi, because 5,6-dichlorobenzimidazole
riboside, emetine, and brefeldin A inhibited the increase in Glu
uptake. Also, injection of emetine and 5,6-dichlorobenzimidazole
into Aplysia prevented long-term sensitization. Synthesis of Glu
itself may be regulated during long-term sensitization because the
same treatments that produced an increase in Glu uptake also
produced a parallel increase in Gln uptake. These results suggest
that coordinated regulation of a number of different processes
may be required to establish or maintain long-term synaptic
facilitation.
The sensorimotor synapse of Aplysia has proven particularlyuseful for the study of the cellular and molecular mechanisms
of long-term facilitation as well as several other types of neural
plasticity (1–3). Thus far, several neuronal properties have been
implicated in long-term memory, including modulation of mem-
brane currents, regulation of transmitter release, and changes in
morphology (4–11). All of these long-term changes are depen-
dent on both transcription and translation (5, 12, 13). Given that
transmitter release is increased during long-term facilitation,
one question that arises is whether other long-term presynaptic
changes such as transmitter uptake and synthesis are coordinated
with increased transmitter release.
An increasing body of evidence indicates that the excitatory
transmitter of the sensorimotor synapse is Glu (14–19). Glu
transporters are poised to impact synaptic efficacy significantly
because the uptake of transmitter represents a major mechanism
whereby neurotransmission is terminated and neurotransmitter
is recycled (20–22). Inhibiting basal Glu uptake affects the
amplitude and duration of postsynaptic potentials and currents
at a number of different synapses including the sensorimotor
synapse of Aplysia (19, 23–27). In addition, blockade of Glu
uptake immediately after aversive training blocks the expression
of long-term memory in the newborn chick (28). These findings
demonstrate that Glu uptake is important for normal synaptic
function and suggest Glu uptake may be involved in expression
of plasticity at glutamatergic synapses. Thus, we hypothesized
that the increased release of transmitter at the sensorimotor
synapse during facilitation is accompanied by an increase in Glu
uptake.
Materials and Methods
Aplysia californica (100–150 g) were obtained from Marinus
(Long Beach, CA) and Alacrity Marine Biological (Redondo
Beach, CA). They were maintained at 15°C under 12-h light/12-h
dark and fed every 2–3 days. Animals were in the lab for 3 days
before use. Experiments investigating duration of siphon with-
drawal after long-term sensitization training or exposure to
5-hydroxytryptamine (5-HT; serotonin) in vivo were performed
as described (6, 11).
Uptake was measured by using a synaptosomal preparation
derived from pleural-pedal ganglia as described (Fig. 3A; ref. 29).
Animals were anesthetized with an injection of isotonic MgCl2.
Pleural-pedal ganglia were removed and trimmed of excess
connective tissue. Synaptosomes were immediately prepared as
the uptake activity declined with time of ganglia in culture. Each
experiment involved synaptosomes from 8–10 ganglia. In exper-
iments on Na1 dependency of uptake, the Na1 of the Ca21-free
seawater [460 mM NaCly10 mM KCly55 mM MgCl2y20 mM
TriszHCl (pH 7.4)y0.1% glucose] was completely replaced with
N-methyl-D-glucamine (Sigma).
Uptake was determined by incubation of 15–30 mg of synap-
tosomal protein for 20 min in Glu ([U-14C], $250 mCiymmol,
ICN), Gln ([U-14C], $200 mCiymmol, NEN) or Leu ([2,3,4,5-
3H], $110 Ciymmol, ICN). Experiments were terminated by
dilution of the synaptosomes with 10 volumes of ice-cold Ca21-
free seawater. Synaptosomes were then centrifuged (16,000 3 g)
for 5 min. The pellet was rinsed three times with 4°C Ca21-free
seawater and dissolved directly in scintillation fluid to determine
total Glu uptake. Uptake was normalized to total protein.
The enrichment of synaptosomes was verified via immunoblot
of synaptophysin, a nerve terminal protein (30), and Ag, a glial
protein (31). Whole fractions and their pellets were solubilized
in 1% SDS and diluted in a 3X loading dye (Bio-Rad). Proteins
were separated by 12% SDSyPAGE, transferred to a poly(vi-
nylidene difluoride) (Bio-Rad) membrane, blocked with 5% dry
milk (Carnation, Glendale, CA), and blotted with either a mAb
against synaptophysin (SY38, 0.7 mgyml, Boehringer Mannheim)
or an affinity-purified polyclonal antiserum against Ag (fraction
4, 1:5,000, a gift from I. Levitan, University of Pennsylvania,
Philadelphia). Immunoreactivity was visualized with a chemilu-
minescent detection system (enhanced chemiluminescence, Am-
ersham International). The horseradish peroxidase-conjugated
secondary antibodies used (Jackson ImmunoResearch, 1:20,000)
were donkey anti-mouse (Synaptophysin) or donkey anti-rabbit
(Ag).
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Ag is a secreted glial protein in Aplysia (31). To ensure that the
immunoblotted Ag was contained within glia or glial fragments,
all fractions were exposed to proteinase K [Sigma; 0.125 mgyml
in artificial seawater: 395 mM NaCly28 mM Na2SO4y10 mM
KCly50 mM MgCl2y10 mM CaCl2y10 mM TriszHCl (pH 8)] to
eliminate extracellular protein. The synaptosomal fractions were
diluted with an equal volume of proteinase K solution, and
incubated at 20°C for 0.5 h. The reaction was then incubated at
4°C for 15 min with PMSF (5 mM, Sigma) to inactivate pro-
teinase K.
Uptake of Glu by synaptosomes was characterized with Glu
uptake inhibitors: DL-threo-b-hydroxyaspartate (THA, Sigma),
pyrrolidine-dicarboxylic acid (Research Biochemicals, Natick,
MA), and aminocyclobutane-dicarboxylic acid (Sigma). All
drugs were dissolved in 1 N NaOH to a final concentration of:
134 mM THAy628 mM pyrrolidine-dicarboxylic acidy251 mM
aminocyclobutane-dicarboxylic acid. Final solutions were made
by adding the drug solution and an equal volume of 1 N HCl to
Ca21-free seawater in which the salt concentrations and pH were
modified to compensate for the addition of the volume of drug
solution.
Glu uptake was measured in sensory neurons cultured as
described (32, 33) at a density of 20–70 neurons per dish.
Neurons were allowed to grow for 5 days before use in a medium
consisting of equal parts isotonic L-15 and hemolymph. To
measure uptake, the medium was replaced with artificial sea-
water [395 mM NaCly28 mM Na2SO4y10 mM KCly50 mM
MgCl2y10 mM CaCl2y30 mM Hepes (pH 7.65)]. After rinsing
with artificial seawater, cultures were incubated in 2 ml of 10 mM
[14C]Glu at 15°C for 30 min. Uptake was terminated by rinsing
in 4°C seawater. Excess solution was quickly removed with a
KimWipe, and cells and their processes were lifted from the
culture plate with scintillation fluid. Glu uptake was normalized
to the number of sensory neurons on the culture dish.
Glu uptake was also studied in groups of 10 isolated pleural-
pedal ganglia. After trimming, pleural-pedal ganglia were ran-
domized and placed into a solution consisting of two parts
isotonic L-15, one part hemolymph, and one part buffered
seawater [Instant Ocean seawater with 30 mM Hepes (pH 7.65)]
(32) for 2 h before the experimental treatments began.
Data on duration of siphon withdrawal 24 h after treatment
with 5-HT, Glu uptake after treatment with 5-HT and electrical
stimulation (Fig. 2), and the effects of brefeldin A on Glu uptake
(Fig. 6) were analyzed with a one-way ANOVA. Post hoc analysis
was performed by using the T-Method of unplanned compari-
sons (Fig. 2), and the Tukey-Kramer procedure (Figs. 4A, 5, and
6). Fractional differences in the increase in uptake caused by
5-HT treatment were analyzed by using Student’s t test (Fig. 3C).
Comparison of Lineweaver–Burk plots was done with an analysis
of covariance (Fig. 1). In all tests, significance was set at P # 0.05.
Results
Characterization of Glu Transporter. The synaptosomal preparation
(P3) from pleural-pedal ganglia exhibited high-affinity Glu
uptake (Fig. 1, solid line). Lineweaver–Burk analysis of the
observed Glu uptake demonstrated a transporter with Km 5 5
mM and Vmax 5 255 fmolymgymin (Fig. 1 Inset), values similar to
those measured in other systems (34). Elimination of sodium
from the extracellular medium inhibited Glu uptake (10 mM) by
98 6 5% (SEM, n 5 4).
The effects of several known Glu uptake inhibitors were
measured. The inhibitors, which are all conformational ana-
logues of Glu, were: THA, pyrrolidine-dicarboxylic acid, and
aminocyclobutane-dicarboxylic acid. The relative potencies of
these drugs to inhibit uptake into synaptosomes were (IC50): 0.03
mM THA . 0.3 mM pyrrolidine-dicarboxylic acid . 1.0 mM
aminocyclobutane-dicarboxylic acid. The efficacy of THA was
also tested in intact ganglia, with an estimated IC50 of 6 mM.
Several reasons may account for the difference in IC50s for THA
measured in synaptosomes and whole ganglia. The connective
tissue sheath of the ganglia may present a diffusional barrier. In
addition, Glu uptake by whole ganglia is via two different
populations of transporters as assessed by Lineweaver–Burk
analysis (data not shown), which may influence the ability of the
drug to inhibit Glu uptake.
Regulation of Glu Transporters. To study the regulation of Glu
uptake, animals were exposed to one of two different treatments
that enhance the siphon withdrawal reflex. The first treatment
examined was an in vivo treatment of 5-HT, which produces
long-term facilitation. Elimination of 5-HT blocks induction of
long-term sensitization (35, 36). In vivo treatment of Aplysia with
5-HT elicits molecular changes associated with long-term sen-
sitization and facilitation (37–39), and elevates the concentration
of 5-HT in the hemolymph to mM levels (40) which are known
to cause facilitation of the sensorimotor synapse in vitro. Bathing
an animal with 500 mM 5-HT for 1.5 h produced a 140% increase
in Glu uptake 24 h after treatment (n 5 5) and a much smaller
increase immediately after the treatment (n 5 4) (Fig. 2, F 5 3.9,
df 5 22, P , 0.02). Treatment with 250 mM 5-HT in vivo also
increased Glu uptake, but the increase in Glu uptake 24 h after
250 mM 5-HT was much less than the increase produced by 500
mM 5-HT (Fig. 2; P , 0.05). In a set of parallel control
experiments, the effect of in vivo 5-HT treatments was investi-
gated on duration of siphon withdrawal; 500 mM 5-HT signifi-
cantly increased the duration of siphon withdrawal 112 6 25%
24 h after treatment (F 5 12.2, df 5 11, P , 0.002), but 250 mM
5-HT did not appear to significantly change the duration of the
reflex response (32 6 9%). Thus, the long-term effects of the two
different concentrations of 5-HT on Glu uptake correlated with
their effects on behavior.
Long-term sensitization of the siphon withdrawal ref lex is
classically produced by electrical stimulation applied to one
side of the body wall (6, 11). Sensitization training led to a
significant long-term (24 h) increase (120%) in Glu uptake in
synaptosomes obtained from pleural-pedal ganglia from the
trained side of the animal compared with control synapto-
Fig. 1. Synaptosomes exhibit high-affinity Glu uptake. Glu uptake was
measured in synaptosomal preparations (P3; see Fig. 3A) derived from pleural-
pedal ganglia. Synaptosomal Glu uptake was measured from control (solid
line, F) and experimental (500 mM 5-HT, dashed line, {) animals 24 h after
treatment. Glu uptake by synaptosomes was dose dependent. Note the ap-
parent increase in Vmax from synaptosomes isolated 24 h after treatment of
animals with 5-HT. (Inset) Lineweaver–Burk analysis of data in main graph.
Each experiment contained synaptosomes derived from 8–10 pleural-pedal
ganglia. In this and subsequent illustrations, error bars are SEM.









somes obtained from contralateral ganglia on the untrained side
of the animal (Fig. 2; n 5 5, P , 0.05). We confirmed in parallel
experiments that electrical stimulation produced unilateral sen-
sitization (Fig. 5). Thus, two different treatments (5-HT and
electrical stimulation) which induced a long-term enhancement
of the siphon-withdrawal reflex significantly increased Glu up-
take in synaptosomes.
Site of Transporter Regulation. To investigate whether the increase
in Glu uptake was caused by glial or neuronal uptake (34), we
compared the relative abundance of glia and nerve terminals
with the effects of 5-HT on Glu uptake in two different fractions
generated by the synaptosomal isolation technique (Fig. 3A).
Immunoblots for the Aplysia glial-specific protein Ag were
performed (31) to determine the presence of glia and immuno-
blots for synaptophysin were used to assess the presence of nerve
terminals (30). Densitometric analysis indicated that Ag was
10-fold enriched in P2 (cellular fraction pellet) relative to P3
(synaptosomal fraction pellet) (Fig. 3B, n 5 3). In contrast,
synaptophysin was threefold enriched in P3 relative to P2 (Fig.
3B, n 5 4).
If the increase in Glu uptake after 5-HT was caused by an
increase in glial uptake, then the increase in Glu uptake should
be larger in the P2 fraction than the P3 preparation. Conversely,
if the increase in Glu uptake was caused by neuronal uptake,
then the increase in Glu uptake should be larger in the P3 than
the P2 preparation. As previously observed, Glu uptake was
significantly increased in P3 (n 5 8), the synaptosomal prepa-
ration, 24 h after treatment with 5-HT (Fig. 3C, t 5 5.9, df 5 11,
P , 0.0002). However, no change in Glu uptake 24 h after
treatment with 5-HT was observed in P2 (n 5 5), the cellular
preparation which contained the most glia (Fig. 3C). The
absence of any effect in the cellular fraction was surprising,
because the cellular fraction has been shown to contain more
total synaptosomes than the synaptosomal fraction (29). The
specific activity of Glu uptake in the cellular fraction is double
that of the synaptosomal fraction (cellular, 520 fmolymgymin;
and synaptosomal, 237 fmolymgymin). However, as indicated by
our Western blots and other studies (29), glial and other
nonsynaptic membrane is highly abundant in the cellular frac-
tion. Therefore, absence of an effect in the cellular fraction is
most likely caused by a masking effect of glial uptake. Because
the synaptosomal fraction has little glial membrane and is
enriched in presynaptic membrane (Fig. 3B), the increase in Glu
uptake characterized in synaptosomes obtained from treated
animals was most likely caused by an increase in neuronal, rather
than glial Glu uptake. It is possible that the cellular compart-
ments which were purified by synaptosomal isolation technique
contained glial or other cellular elements which did not express
Ag or synaptophysin. Therefore, we used cultures of isolated
sensory neurons to investigate whether 5-HT could elicit an
increase in Glu uptake specifically in sensory neurons.
The effect of 5-HT on Glu uptake was measured in individual
cultures of sensory neurons. No other cell types were present in
Fig. 2. Glu uptake is regulated by 5-HT and sensitization training. Glu uptake
was measured from synaptosomes immediately and 24 h after a 1.5-h treat-
ment in vivo with either 250 or 500 mM 5-HT, or long-term sensitization
training (electrical stimulation). Immediately after treatment with either 250
(n 5 7) or 500 mM 5-HT (n 5 4), Glu uptake was modestly increased. However,
500 mM 5-HT (n 5 5) and sensitization training (n 5 5) had a large, significant
effect on uptake 24 h after treatment. The effects of 500 mM 5-HT and
sensitization training were significantly larger than the effect of 250 mM 5-HT
24 h after treatment (n 5 4). All increases in Glu uptake were significantly
different from no change. An asterisk (*) indicates the change in uptake was
significantly (P , 0.05) different from the effect of 250 mM 5-HT.
Fig. 3. Increases in Glu uptake were caused by neuronal Glu transporters. Glu
uptake in two fractions generated by the synaptosomal isolation technique
and in cultured sensory neurons was studied to determine if increases in Glu
uptake were neuronal or glial. (A) A flow chart of the isolation technique for
the synaptosome (P3) and cellular (P2) preparations. (B) Immunoblots of P2
(Left) and P3 (Right) preparations for Ag, a glial protein, and synaptophysin,
a nerve terminal protein. Ag is at least tenfold enriched in the cellular (P2)
relative to the synaptosomal (P3) preparation (n 5 3). Synaptophysin is en-
riched at least threefold in the P3 relative to the P2 preparation (n 5 4). Only
one immunoreactive band was seen for both Ag and synaptophysin. Analysis
of the Coomassie-stained transferred gel was used to verify equal protein
loading. (C) Glu uptake in the P2 and P3 preparations 24 h after treatment in
vivo with 500 mM 5-HT. Glu uptake was increased in the synaptosomal (n 5 8),
but not the cellular preparation (n 5 5). There was a significant increase in Glu
uptake by cultured sensory neurons 24 h after treatment with 5-HT (n 5 4).
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the cultures. Sensory neurons exhibited sodium-dependent Glu
uptake (data not shown). Treatment of the cultures with 50 mM
5-HT for 1.5 h produced a significant 130% increase in Glu
uptake 24 h after the treatment (Fig. 3C; df 5 3, P , 0.05). Thus,
5-HT can produce an increase in Glu uptake in sensory neurons.
Specificity of Transporter Regulation. The increase observed in
synaptosomal Glu uptake after exposure to 5-HT or sensitization
training could be caused by an increase in sodium-dependent or
sodium-independent uptake. We found that Glu uptake in the
absence of extracellular sodium was unaffected by in vivo 5-HT
treatments (Fig. 4A; t 5 1.31, df 5 5, P , 0.25). Therefore,
long-term increases in Glu uptake produced by 5-HT were
caused by sodium-dependent uptake mechanisms.
To investigate the possibility that transport of amino acids
other than Glu was regulated, uptake of Leu and Gln was
examined. Leu serves as a marker for general amino acid uptake
because it is not transported via a high-affinity transporter. Leu
uptake was unaffected by treatments in vivo with 5-HT (Fig. 4A;
t 5 0.50, df 5 3, P , 0.65).
In the central nervous system, glia take up Glu and convert it
to Gln via glutamine synthetase, an enzyme which is also found
in Aplysia glia (41). Gln is then released by glia and taken up by
neurons as a precursor for synthesis of Glu or as an energy
source. We found that Gln uptake was significantly increased
150% by treatment with 5-HT (Fig. 4A; t 5 3.25, df 5 5, P ,
0.05). Regulation of Gln transport appeared to be neuronal
because the effect of 5-HT on Gln uptake was observed only in
the P3 preparation (see above) and not in the P2 preparation
(P2 5 220.38 6 10.53%, t 5 1.94, df 5 2, P , 0.20). The increase
in synaptosomal Gln uptake could be caused by the increase in
activity of the Glu transporter. However, Gln uptake was not
inhibited by molar excess Glu (Fig. 4B). In addition, Glu uptake
was not inhibited by molar excess Gln (Fig. 4C). These results
indicate that Glu and Gln transporters are different entities.
Mechanism of Regulation. To determine whether the Km or Vmax of
the Glu transporter was affected by 5-HT, animals were treated
with 5-HT and the kinetics of Glu uptake from synaptosomes
were measured. The Vmax of Glu uptake was significantly in-
creased approximately threefold 24 h after treatment with 500
mM 5-HT (795 fmolymgymin, Fig. 1, dashed line; F 5 3.72, df 5
90, P , 0.05). However, the Km for Glu uptake (6 mM) was not
significantly different from control values (5 mM) (t 5 0.53, df 5
90, P , 0.8).
Increases in Vmax could be caused by insertion of transporters
into the plasma membrane which were cytosolic before induction
of long-term sensitization (42), or newly synthesized transporters
could be added to the membrane via movement through the
Golgi and transport to the nerve terminal (43–45). The time
course of the increase in Glu uptake suggested synthesis of new
proteins and their subsequent transport to the nerve terminal
(Fig. 2). To test this hypothesis, animals were injected with
emetine (1 ml, 9 mMy140 g body weight), a protein synthesis
inhibitor, or DRB (3 ml, 2 mMy100 g body weight), a mRNA
synthesis inhibitor (46), before receiving long-term sensitization
training. The experimentor who measured the duration of siphon
withdrawal was blind to the side that received electrical stimu-
lation and the solution which was injected into the animal.
Injection of emetine into an intact Aplysia has previously been
shown to inhibit protein synthesis within 0.5 h by greater than
90% in pleural-pedal ganglia (40). Injection of DRB inhibited
RNA synthesis by 50 6 7% (SEM, n 5 3) within 0.5 h as assayed
by incorporation of uridine into trichloroacetic acid-precipitable
material (46). Long-term sensitization training increased by
130% the duration of siphon withdrawal elicited from the side of
the animal which received the training (Fig. 5), but not the
contralateral side (5 6 3%, n 5 5). Injection of animals with
emetine or DRB 30 min before electrical stimulation signifi-
cantly inhibited sensitization of the siphon withdrawal reflex
(Fig. 5; df 5 10, P , 0.05). Duration of the siphon withdrawal
elicited from the untreated side of the animal was not affected
by emetine (6 6 3%, n 5 3) or DRB (14 6 20%). The large
increase in Glu uptake normally seen 24 h after sensitization
training (Fig. 3B, replotted in Fig. 5) was significantly inhibited
by injection of emetine (n 5 4) or DRB (n 5 3) before electrical
stimulation (Fig. 5, P , 0.05). Emetine or DRB injection alone
did not affect basal Glu uptake [(in fmolymgymin) control, 469 6
84; emetine, 435 6 29; DRB, 400 6 40] suggesting that synaptic
Glu transporters have a relatively slow turnover rate. These
results indicate that synthesis of mRNA and protein is required
for the increase in Glu uptake. However, because both mRNA
and protein synthesis are required for induction of long-term
facilitation, the requirement for protein and mRNA synthesis
may occur at earlier steps and not the synthesis of new
transporters.
To further investigate the possible role of Glu transporter
synthesis, isolated pleural-pedal ganglia were exposed to 5-HT
and then brefeldin A, a specific inhibitor of endoplasmic retic-
ulum-Golgi transfer (47) which has no effect on delivery of
glucose transporters to the plasma membrane by exocytosis (48).
Fig. 4. Specificity of increases in Glu uptake. (A) The increase in synaptoso-
mal Glu uptake produced by 500 mM 5-HT (n 5 12) was not observed when
sodium was removed from the extracellular media (n 5 6). Synaptosomal
uptake of Leu was not affected by 5-HT in vivo (n 5 4). Synaptosomal Gln
uptake was significantly increased by 5-HT in vivo (n 5 6). (B) Gln uptake was
inhibited by excess Gln, but not by excess Glu, indicating that Gln uptake was
through a Gln transporter. (C) Glu uptake was inhibited by excess Glu, but not
by excess Gln, indicating that Glu uptake was through a Glu transporter.









Treatment of isolated pleural-pedal ganglia with 50 mM 5-HT
induced an increase in synaptosomal Glu uptake 24 h after
treatment (Fig. 6; F 5 4.17, df 5 23, P , 0.01). Treatment of
pleural-pedal ganglia with brefeldin A inhibited the increase in
Glu uptake caused by 5-HT (Fig. 6, n 5 5, P , 0.05). Treatment
with brefeldin A alone did not change Glu uptake, providing
further evidence that synaptic Glu transporters have a slow
turnover rate (Fig. 6, n 5 5). Together, the results obtained with
emetine and brefeldin A suggest that long-term regulation of Glu
transporters may involve synthesis of new transporters and their
transfer through the Golgi. It should be noted that brefeldin A
has been shown to inhibit long-term potentiation in area CA1 of
the hippocampus 3 h after induction (49); therefore, brefeldin A
may inhibit the increase in Glu uptake by blocking an induction
event involved in the pathway responsible for long-term regu-
lation of Glu uptake. Further work is required to distinguish
between the possible mechanisms of action of DRB, emetine,
and brefeldin A on long-term regulation of Glu uptake.
Discussion
Treatments that induce long-term facilitation or behavioral
sensitization increased neuronal Glu uptake. This increase in
Glu uptake occurred in sensory neurons and appears to be
caused by an increase in the number of Glu transporters. An
increase in the number of transporters could be caused by
insertion of additional transporters at existing sensorimotor
synapses (42–45), an increase in the size or number of synapses
(7, 8), or a combination of these possibilities. First, 1 day of
sensitization training, which is what was used in our experiments,
does not induce significant morphological change in sensory
neurons of the abdominal (7, 8) or pleural-pedal ganglia (50).
Morphological change has only been observed after 4 days of
sensitization training (7, 8, 50). Second, in our synaptosomal
preparation, results are normalized for protein, potentially re-
moving any increase that may be caused by addition of new
terminals. However, the small amount of protein new terminals
would contribute and the heterogeneity of the synaptosomal
preparation (29) make it difficult to exclude the possibility that
growth of new synapses partially contributes to the increase in
synaptosomal Glu uptake. Finally, although application of 5-HT
does not increase the number of varicosities in isolated sensory
neurons (10), we observed changes in uptake in isolated sensory
neurons. It should be noted that the concentration of 5-HT used
in the aforementioned study was 10 times lower than the
concentration used in our study. Thus, it is possible that growth
might account for a portion of the increase in Glu uptake we
observed in neuronal cultures. Altogether, it seems as if the
increase in Glu uptake and the number of transporters in the
membrane we observed was not caused by growth of new
terminals. However, we cannot rule out that growth may partially
account for the increase in Glu uptake.
Termination of neurotransmission at glutamatergic synapses
occurs via diffusion and the action of synaptic Glu transporters
(20, 21). Long-term facilitation of the sensorimotor synapse of
Aplysia is caused, in part, by an increase in the release of
neurotransmitter which appears to be Glu (9, 14–19). Increases
in Glu uptake concomitant with increases in Glu release may
have several important functions. Increasing Glu uptake could
prevent extrasynaptic diffusion of Glu from active synapses (51).
Diffusion of Glu outside of the synaptic cleft may activate
presynaptic metabotropic receptors (52–54) or Glu receptors
within neighboring synapses (51). The activity of Glu transport-
ers may also impact the duration of the excitatory postsynaptic
potential (19, 55). More importantly, increases in Glu uptake
may act to prevent depletion of transmitter andyor desensitiza-
tion of synaptic Glu receptors (22, 27, 56–62), and may also
supply additional Glu for energy metabolism. Thus, Glu trans-
porters may play an important role in maintaining an increased
efficacy of transmission at glutamatergic synapses.
The increase in Gln uptake may serve several functions.
Increased release of Glu caused by facilitation of neurotrans-
mitter release may require increased production of Glu from Gln
to maintain the neurotransmitter pool. Gln also could be used
for production of energy via the tricarboxylic acid cycle and may
serve as a source of nitrogen for the biosynthesis of several
nitrogen-containing compounds. Finally, some studies have im-
plicated Gln in the synthesis of nitric oxide via Arg.¶ NO has
been implicated in several examples of neuronal plasticity
(63–67).
¶O’Dowd, Y. & Newsholme, P. (1997) Biochem. Soc. Trans. 25, 403S (abstr.).
Fig. 5. Emetine and DRB block long-term sensitization and the long-term
increase in Glu uptake. Electrical stimulation applied to one side of an animal
induced long-term sensitization of the siphon withdrawal reflex 24 h after
stimulation (F 5 12.98, df 5 13, P , 0.0005). Injection of emetine (n 5 3) or DRB
(n 5 3) into Aplysia 30 min before electrical stimulation significantly inhibited
the appearance of long-term sensitization (P , 0.05). The long-term increase
in Glu uptake produced by electrical stimulation (n 5 5) was significantly
inhibited by injection of emetine (n 5 4, P , 0.05) or DRB (n 5 3, P , 0.05).
Fig. 6. Brefeldin A blocks the long-term increase in Glu uptake. Synaptoso-
mal Glu uptake was significantly increased 24 h after treatment of pleural-
pedal ganglia with 5-HT in vitro (n 5 7). Exposure to brefeldin A (18 mM) for
24 h, beginning immediately after the treatment blocked the increase in
Glu uptake (n 5 5). Brefeldin A treatment alone had no effect on Glu uptake
(n 5 5).
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Regulation of the Glu and Gln transporters by treatments
which cause long-term sensitization in Aplysia indicate that
neurotransmitter uptake and synthesis may be important for
expression of plasticity and therefore be coregulated with trans-
mitter release. In support of this hypothesis, results indicate that
regulation of Glu uptake also occurs in area CA1 of the
hippocampus during long-term potentiation (68). Thus, regula-
tion of Glu uptake during increases in synaptic efficacy such as
long-term facilitation in Aplysia and long-term potentiation in
mammals may be a phylogenetically conserved phenomenon.
Moreover, these transporters provide new molecular correlates
which can now be used to study mechanisms involved in long-
term changes related to the formation of memory. Our findings
present an opportunity to study the long-term regulation of
neurotransmitter transporters because relatively little is known
regarding these mechanisms in either long-term memory or
other instances such as neurodegenerative disorders (69) or
severe brain trauma (70), where regulation of transporters seems
to be involved.
The authors thank J. Liu, X. Ren, and C. Tehlirian for technical
assistance. The Ag antibodies used in this study were a generous gift from
Dr. I. Levitan. This work was supported by National Institutes of Health
Grants NS28462 to A.E. and NS19895 to J.H.B.
1. Byrne, J. H., Baxter, D. A., Buonomano, D. V., Cleary, L. J., Eskin, A.,
Goldsmith, J. R., McClendon, E., Nazif, F. A., Noel, F. & Scholz, K. P. (1991)
Ann. N. Y. Acad. Sci. 627, 124–149.
2. Bailey, C. H., Bartsch, D. & Kandel, E. R. (1996) Proc. Natl. Acad. Sci. USA
93, 13445–13452.
3. Abel, T., Martin, K. C., Bartsch, D. & Kandel, E. R. (1998) Science 279,
338–341.
4. Bailey, C. H. & Chen, M. (1983) Science 220, 91–93.
5. Dale, N., Kandel, E. R. & Schacher, S. (1987) J. Neurosci. 7, 2232–2238.
6. Scholz, K. P. & Byrne, J. H. (1987) Science 235, 685–687.
7. Bailey, C. H. & Chen, M. (1988) Proc. Natl. Acad. Sci. USA 85, 9356–9359.
8. Bailey, C. H. & Chen, M. (1988) Proc. Natl. Acad. Sci. USA 85, 2373–2377.
9. Dale, N., Schacher, S. & Kandel, E. R. (1988) Science 239, 282–285.
10. Glanzman, D. L., Kandel, E. R. & Schacher, S. (1990) Science 249, 799–802.
11. Cleary, L. J., Lee, W. L. & Byrne, J. H. (1998) J. Neurosci. 18, 5988–5998.
12. Montarolo, P. G., Goelet, P., Castellucci, V. F., Morgan, J., Kandel, E. R. &
Schacher, S. (1986) Science 234, 1249–1254.
13. Bailey, C. H., Montarolo, P., Chen, M., Kandel, E. R. & Schacher, S. (1992)
Neuron 9, 749–758.
14. Dale, N. & Kandel, E. R. (1993) Proc. Natl. Acad. Sci. USA 90, 7163–7167.
15. Lin, X. Y. & Glanzman, D. L. (1994) Proc. R. Soc. London B 255, 215–221.
16. Zhu, H., Wu, F. & Schacher, S. (1997) J. Neurosci. 17, 4976–4986.
17. Armitage, B. A. & Siegelbaum, S. A. (1998) J. Neurosci. 18, 8770–8779.
18. Levenson, J., Sherry, D. M., Dryer, L., Chin, J., Byrne, J. H. & Eskin, A. (2000)
J. Comp. Neurol. 423, 121–131.
19. Burdohan, J., Levenson, J., Eskin, A. & Byrne, J. H. (1998) Soc. Neurosci. Abstr.
24, 1701.
20. Schousboe, A. (1981) Int. Rev. Neurobiol. 22, 1–45.
21. Nicholls, D. & Attwell, D. (1990) Trends Pharmacol. Sci. 11, 462–468.
22. Otis, T. S., Wu, Y. C. & Trussell, L. O. (1996) J. Neurosci. 16, 1634–1644.
23. Hestrin, S., Sah, P. & Nicoll, R. A. (1990) Neuron 5, 247–253.
24. Barbour, B., Keller, B. U., Llano, I. & Marty, A. (1994) Neuron 12, 1331–1343.
25. Tong, G. & Jahr, C. E. (1994) Neuron 13, 1195–1203.
26. Diamond, J. S. & Jahr, C. E. (1997) J. Neurosci. 17, 4672–4687.
27. Turecek, R. & Trussell, L. O. (2000) J. Neurosci. 20, 2054–2063.
28. Ng, K. T., O’Dowd, B. S., Rickard, N. S., Robinson, S. R., Gibbs, M. E., Rainey,
C., Zhao, W. Q., Sedman, G. L. & Hertz, L. (1997) Neurosci. Biobehav. Rev.
21, 45–54.
29. Chin, G. J., Shapiro, E., Vogel, S. S. & Schwartz, J. H. (1989) J. Neurosci. 9,
38–48.
30. Chin, G. J., Vogel, S. S., Elste, A. M. & Schwartz, J. H. (1990) Brain Res. 508,
265–272.
31. Lockhart, S. T., Levitan, I. B. & Pikielny, C. W. (1996) J. Neurobiol. 29, 35–48.
32. Schacher, S. & Proshansky, E. (1983) J. Neurosci. 3, 2403–2413.
33. Chin, J., Angers, A., Cleary, L. J., Eskin, A. & Byrne, J. H. (1999) Learn. Mem.
6, 317–330.
34. Kanai, Y., Smith, C. P. & Hediger, M. A. (1993) FASEB J. 7, 1450–1459.
35. Walters, E. T., Byrne, J. H., Carew, T. J. & Kandel, E. R. (1983) J. Neurophysiol.
50, 1543–1559.
36. Glanzman, D., Mackey, S., Hawkins, R., Dyke, A., Lloyd, P. & Kandel, E.
(1989) J. Neurosci. 9, 4200–4213.
37. Alberini, C. M., Ghirardi, M., Metz, R. & Kandel, E. R. (1994) Cell 76,
1099–1114.
38. Hegde, A. N., Inokuchi, K., Pei, W., Casadio, A., Ghirardi, M., Chain, D. G.,
Martin, K. C., Kandel, E. R. & Schwartz, J. H. (1997) Cell 89, 115–126.
39. Bartsch, D., Casadio, A., Karl, K. A., Serodio, P. & Kandel, E. R. (1998) Cell
95, 211–223.
40. Levenson, J., Byrne, J. H. & Eskin, A. (1999) J. Neurosci. 19, 8094–8103.
41. Roots, B. I. (1981) J. Exp. Biol. 95, 167–180.
42. Corey, J. L., Davidson, N., Lester, H. A., Brecha, N. & Quick, M. W. (1994)
J. Biol. Chem. 269, 14759–14767.
43. Ramamoorthy, S., Cool, D. R., Mahesh, V. B., Leibach, F. H., Melikian, H. E.,
Blakely, R. D. & Ganapathy, V. (1993) J. Biol. Chem. 268, 21626–21631.
44. Ramamoorthy, J. D., Ramamoorthy, S., Papapetropoulos, A., Catravas, J. D.,
Leibach, F. H. & Ganapathy, V. (1995) J. Biol. Chem. 270, 17189–17195.
45. Rattray, M., Wotherspoon, G., Savery, D., Baldessari, S., Marden, C., Priestley,
J. V. & Bendotti, C. (1994) Eur. J. Pharmacol. 268, 439–442.
46. Raju, U., Koumenis, C., Nunez-Regueiro, M. & Eskin, A. (1991) Science 253,
673–675.
47. Chardin, P. & McCormick, F. (1999) Cell 97, 153–155.
48. Bao, S., Smith, R. M., Jarett, L. & Garvey, W. T. (1995) J. Biol. Chem. 270,
30199–30204.
49. Matthies, H., Jr., Kretlow, J., Matthies, H., Smalla, K. H., Staak, S. & Krug, M.
(1999) Neuroscience 91, 175–183.
50. Wainwright, M. L., Zhang, H., Byrne, J. H. & Cleary, L. J. (1997) Soc. Neurosci.
Abstr. 23, 1334.
51. Asztely, F., Erdemli, G. & Kullmann, D. M. (1997) Neuron 18, 281–293.
52. Cochilla, A. J. & Alford, S. (1998) Neuron 20, 1007–1016.
53. Dube, G. R. & Marshall, K. C. (2000) J. Neurophysiol. 83, 1141–1149.
54. Abdul-Ghani, A. S., Attwell, P. J., Singh Kent, N., Bradford, H. F., Croucher,
M. J. & Jane, D. E. (1997) Brain Res. 755, 202–212.
55. Mennerick, S. & Zorumski, C. F. (1994) Nature (London) 368, 59–62.
56. Kiskin, N. I., Krishtal, O. A. & Tsyndrenko, A. (1986) Neurosci. Lett. 63,
225–230.
57. Dudel, J., Franke, C., Hatt, H., Ramsey, R. L. & Usherwood, P. N. (1988)
Neurosci. Lett. 88, 33–38.
58. Trussell, L. O., Thio, L. L., Zorumski, C. F. & Fischbach, G. D. (1988) Proc.
Natl. Acad. Sci. USA 85, 4562–4566.
59. Tang, C. M., Dichter, M. & Morad, M. (1989) Science 243, 1474–1477.
60. Trussell, L. O. & Fischbach, G. D. (1989) Neuron 3, 209–218.
61. Raman, I. M. & Trussell, L. O. (1995) Biophys. J. 68, 137–146.
62. Otis, T., Zhang, S. & Trussell, L. O. (1996) J. Neurosci. 16, 7496–7504.
63. Muller, U. (1996) Neuron 16, 541–549.
64. Kendrick, K. M., Guevara-Guzman, R., Zorrilla, J., Hinton, M. R., Broad,
K. D., Mimmack, M. & Ohkura, S. (1997) Nature (London) 388, 670–674.
65. Rickard, N. S., Ng, K. T. & Gibbs, M. E. (1998) Neurobiol. Learn. Mem. 69,
79–86.
66. Lewin, M. R. & Walters, E. T. (1999) Nat. Neurosci. 2, 18–23.
67. Zhuo, M., Laitinen, J. T., Li, X. C. & Hawkins, R. D. (1999) Learn. Mem. 6,
63–76.
68. Levenson, J., Weeber, E., Selcher, J., Kategaya, L., Sweatt, J. & Eskin, A.
(2000) Soc. Neurosci. Abstr. 26, 1590.
69. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W.
(1995) Ann. Neurol. 38, 73–84.
70. Rossi, D. J., Oshima, T. & Attwell, D. (2000) Nature (London) 403, 316–321.
Levenson et al. PNAS u November 7, 2000 u vol. 97 u no. 23 u 12863
N
EU
RO
BI
O
LO
G
Y
